CooperCompanies Q1 adjusted EPS beats estimates on improved margins

Overview

• Medical device company's fiscal Q1 revenue slightly missed analyst expectations

• Adjusted EPS for fiscal Q1 beat analyst expectations

• Company repurchased $92.5 mln of common stock during the quarter

Outlook

• Company projects fiscal 2026 revenue of $4.306 bln to $4.346 bln

• CooperCompanies expects fiscal 2026 non-GAAP EPS of $4.58 to $4.66

• Company anticipates fiscal 2026 free cash flow of $600 mln to $625 mln

Result Drivers

• PREMIUM PORTFOLIO - Revenue growth driven by strength in premium MyDay portfolio and new product launches, including MyDay MiSight

• OPERATING MARGINS - Improved operating margins due to disciplined execution and synergies from last year's reorganization

• FREE CASH FLOW - Strong free cash flow supported share repurchases, aligning with capital allocation strategy

Company press release: ID:nGNX56NQH2

Key Details

*Applies to a deviation of less than 1%; not applicable for per-share numbers.

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 12 "strong buy" or "buy", 8 "hold" and 1 "sell" or "strong sell"

• The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

• Wall Street's median 12-month price target for Cooper Companies Inc is $92.50, about 12.8% above its March 4 closing price of $81.98

• The stock recently traded at 18 times the next 12-month earnings vs. a P/E of 18 three months ago

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.